key: cord-0745465-3plur8jv authors: Port, Andreas; Shaw, Jamie V.; Klopp‐Schulze, Lena; Bytyqi, Afrim; Vetter, Claudia; Hussey, Elizabeth; Mammasse, Nadra; Ona, Victor; Bachmann, Angelika; Strugala, Denis; Reh, Christian; Goteti, Kosalaram title: Phase 1 study in healthy participants of the safety, pharmacokinetics, and pharmacodynamics of enpatoran (M5049), a dual antagonist of toll‐like receptors 7 and 8 date: 2021-08-19 journal: Pharmacol Res Perspect DOI: 10.1002/prp2.842 sha: a7d24762717f1147ba41301562f8c521a4c939c5 doc_id: 745465 cord_uid: 3plur8jv This study evaluated the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single and multiple oral doses of enpatoran (formerly named M5049), a new toll‐like receptor (TLR) 7 and 8 dual antagonist, and the effect of food on a single dose in healthy participants. In this single phase 1, randomized (3:1), double‐blind, placebo‐controlled study, 96 participants received single and multiple ascending oral doses of enpatoran. Participants in single‐dose cohorts received one dose of enpatoran (1, 3, 9, 25, 50, 100, or 200 mg) or placebo using a sentinel dosing strategy. Multiple‐dose cohorts received enpatoran (9, 25, or 200 mg once daily, or 25 or 50 mg twice daily) or placebo for 14 days. Safety, tolerability, PK, and PD (ex vivo‐stimulated cytokine secretion) were assessed in both parts. The effect of food was assessed in an open‐label, one‐way crossover study in the 25 mg single‐dose cohort. Single‐ and multiple‐oral doses of enpatoran up to 200 mg were well tolerated and no significant dose‐limiting adverse events or safety signals were observed under fasting or fed conditions. PK parameters were linear and dose‐proportional across the dose range evaluated, with a slightly delayed absorption and lower peak concentration observed at 25 mg with food. Exposure‐dependent inhibition of ex vivo‐stimulated interleukin‐6 secretion was observed, with maximum inhibition at 200 mg. Enpatoran was well tolerated at doses up to 200 mg. Further investigation of enpatoran is warranted as a potential treatment for diseases driven by TLR7/8 overactivation, such as systemic lupus erythematosus and COVID‐19 pneumonia. Toll-like receptors (TLRs) are a family of conserved transmembrane pattern recognition receptors that are widely expressed in a variety of immune cells and play a key role in both the innate immune response and development of antigen-specific acquired immunity against a range of foreign molecules. TLR7 and TLR8 are intracellular receptors expressed in the cell endosome that bind single-stranded ribonucleic acids (RNAs) from viruses, and are involved in the normal defense response against these pathogens. 1 Studies suggest that TLR7 and TLR8 may each have specialized roles and induce an immune response via different mechanisms. [2] [3] [4] [5] In addition to having slightly different ligand binding characteristics and cellular expression patterns, TLR7 and TLR8 also differentially activate the pro-inflammatory mediators interferon (IFN) regulatory factor (IRF) and nuclear factor-kappa B (NF-κB), eliciting cell typespecific responses. 2 Whilst TLR7 shows dual activation of both the IRF and NF-κB pathways and the production of interferon-alpha (IFNα) and interleukin-6 (IL-6), TLR8 shows a bias toward greater activation of the NF-κB pathway and the production of IL- 6. 2 Aberrant activation of the TLR7 and TLR8 pathways by endogenous RNA molecules may be pathogenic, resulting in the production of Type I IFN, IL-6 and other pro-inflammatory mediators, and the production of autoantibodies, thus leading to the development of certain autoimmune diseases. [6] [7] [8] [9] [10] For example, single nucleotide polymorphisms in both the TLR7 and TLR8 genes have been identified that are associated with systemic lupus erythematosus (SLE), 11 and TLR7 overexpression and knockout studies suggest that TLR7 may promote SLE in mice. [12] [13] [14] [15] Inhibition of TLR7 and TLR8 activation therefore represents a potential therapeutic target for patients with autoimmune diseases that are characterized by overactivation of these receptors, including SLE. 6, 7 It is now understood that TLR signaling is an important mediator of coronavirus disease 2019 (COVID-19) immunopathogenesis. 16 Molecular docking studies suggest that spike protein, the major infective protein of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus, binds to various cell surface TLRs (TLR1, TLR4, and TLR6) that are subsequently involved in the induction of pro-inflammatory responses. 17 In addition, it is possible that activation of TLR7 and TLR8 by SARS-CoV-2 may contribute to the overt inflammatory response that can lead to a cytokine storm in COVID-19 pneumonia, which is a major factor in COVID-19 morbidity and mortality. [18] [19] [20] TLR antagonists are therefore of interest for the treatment of COVID-19 since they may reduce the cytokine storm in infected individuals through inhibition of TLR-mediated pro-inflammatory signaling. 16, 19 Due to the specific and differing expression patterns and molecular functions of TLR7 and TLR8, it has been suggested that a dual TLR7/8 inhibitor may provide superior efficacy in reducing inflammation and autoimmune disease activity than agents targeting either TLR isotype alone. 2 Enpatoran, previously known as M5049, is a potential first-in-class small molecule dual TLR antagonist having activity against both TLR7 and TLR8, which has been shown to inhibit the activation of TLR7/8 in vitro and ex vivo and to suppress disease activity in mouse models of SLE. 21 Enpatoran, therefore, has the potential to inhibit the pathological activity of immune complexes and the progression of autoimmune diseases in the clinical setting. The aim of this phase 1, first-in-human (FIH) study was to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single and multiple doses of enpatoran, and to explore the effect of food on a single dose of enpatoran in healthy participants. This was a phase 1, double-blind, randomized, placebo-controlled study, and the first to use enpatoran in humans (ClinicalTrials.gov NCT03676322). Healthy participants were randomized (3:1) to receive single and multiple ascending doses (SAD and MAD, respectively) of orally administered enpatoran solution or placebo. The study comprised three distinct parts ( Figure 1 ). See the Data S1 for information on the starting dose justification, dose escalation criteria, and blinding. In Part A, participants were randomized to single doses of enpatoran (1, 3, 9, 25, 50 , 100, and 200 mg; named Part A Cohorts 1-7, respectively) or placebo. Two participants in each cohort served as sentinel participants; one received placebo and the other received enpatoran. The remaining six participants in each cohort were randomized following review of 24-h safety data by blinded investigators. Part A consisted of an 18-day screening period, a 7-day in-house period with a single dose on Day 1, and a 14-day safety follow-up period. Each dose was administered after an overnight fast of at least 10 h and was followed by a 4-h post-dose fast. In Part B, participants were randomized to 9, 25, No participants were included in more than one cohort in any part of the study except for those enrolled in SAD Cohort 4, who crossed over to Part C. The study was performed in accordance with the ethical princi- The primary study objectives were to evaluate the safety and tolerability of single and multiple oral doses of enpatoran and explore the effect of food on enpatoran PK parameters in healthy participants. Secondary objectives included the assessment of enpatoran PK parameters following single-and multiple-dose administration, and evaluation of the safety and tolerability of enpatoran under fed conditions. Exploratory objectives included investigation of the PD effects (ex vivo-stimulated cytokine secretion) of single and multiple doses of enpatoran compared with placebo. Inclusion and exclusion criteria were standard for a healthy volunteer study. Healthy male and female participants aged 18-45 years, with body mass index (BMI) 18.5-29.9 kg/m 2 inclusive, and body weight 50-100 kg were eligible. All relevant medical and nonmedical conditions were taken into consideration when deciding whether an individual was eligible for the study. Participants were required to be nonsmokers for at least 90 days before screening. Female participants were only eligible if they were not of childbearing potential. Male participants had to agree to have their female partners use a highly effective contraception method 2 days before the first dose of study intervention until at least 14 weeks after the last dose. Key exclusion criteria included completion of oral anti-infectives within 2 weeks prior to screening, any clinically significant infection or travel to regions with Zika virus or yellow fever within 4 weeks prior to screening, and vaccination within 3 months prior to the first treatment administration. The nature, incidence, and severity of treatment-emergent adverse events (TEAEs) were assessed and recorded continuously throughout the study and at the end of the 14-day safety follow-up period. Safety assessments included physical and neurological examination, F I G U R E 1 Study design and dose escalation scheme. Eight participants were randomized to each cohort; six to active treatment and two to placebo. Eight participants in Part A, Cohort 4, crossed over to Part C. a The primary observation period was reduced to 17 days for Cohorts 3-5 of Part B, since available clinical data showed this timeframe provided sufficient safety and tolerability monitoring; b Single-dose cohort escalation (Part A): safety data from a single dose plus 1 week in-house; c Multiple-dose cohort escalation (Part B): safety data from 2 weeks of treatment until the end of the in-house period. BID, twice daily; QD, once daily vital signs, 12-lead safety electrocardiograms (ECGs), QT and concentration-QT analysis (Holter ECGs), and clinical laboratory parameters. In Parts A and C, 12-lead ECGs were recorded during screening, Day −1 to Day 4 of the in-house period and during the safety follow-up period. In Part B, 12-lead ECGs were recorded during screening, on Days −1, 1, 3, 5, 8, 11, and 14 of the in-house period and during the safety follow-up period. In Parts A and B, digital Holter ECGs were performed from baseline (prior to the first dose of study intervention) through 24 h. In Part B, Cohorts 3, 4, and 5, Holter ECGs were also recorded on Day 14. Concentration-QT analysis was conducted using data collected by digital Holter ECGs and time-matched enpatoran concentrations. A linear mixed effects model with fixed and random slope for concentration, as well as fixed and random intercept and the ΔQTcF (delta QT interval corrected using Fridericia's formula) as the response was fitted to explore the relationship between enpatoran exposure and the corrected QT interval (QTc). Concentrations of enpatoran in the plasma were analyzed using a validated liquid chromatography-tandem mass spectrometry method. Depending on the expected concentration of enpatoran, samples were analyzed using either a low range method (20-50,000 pg/ml) or high range method (1-10,000 ng/ml). The lower limits of quantification (LLOQs) were 20 pg/ml and 1 ng/ ml for the respective methods. Accuracy ranged between 93.1% and 105.5%, and the acceptance criteria for precision was ≤15.0%. A range of PK parameters were calculated using standard non-compartmental methods under both fasting (Parts A and B) and fed (Part C) conditions, including: maximum plasma con- Precision was determined by measuring all levels of controls in replicate over a minimum of 3 days. The acceptance criteria for precision were ≤20% coefficient of variation of quality control samples (n = 3). The LLOQ was determined by performing twofold serial dilutions of standard solutions for a total of eight dilutions; the standards were tested in triplicate over three runs and the LLOQ threshold was determined as the concentration at which the coefficient of variation for the dilution was 30%. For demographic, baseline and safety assessments, continuous measurements were summarized using descriptive statistics and, for categorical data, by means of frequency tables. The safety analysis set comprised all study participants who received at least one dose of enpatoran or placebo. Enpatoran concentrations in plasma and PK parameters were Food effect was analyzed using a linear mixed model, with treatment group as a fixed effect and subject as a random effect, for logtransformed C max and AUC 0-t . This study was conducted between October 15, 2018 and All participants received the assigned treatment and completed the study. Overall, the mean (range) age was 31 (18-45) years and the mean BMI was 24.6 (18.9-29.8) kg/m 2 ; distributions of age and BMI were comparable across the different parts of the study and the placebo groups (Table 1) . Two participants were female and 94 were male, and all were white. No relevant medical history was recorded. During Parts A and B, 13 of the 96 participants reported a total of 21 TEAEs; no TEAEs were reported during Part C of the study. The incidence of TEAEs in single-and multiple-dose cohorts were similar (Tables 2 and 3 ). All TEAEs were mild to moderate and resolved without sequelae. No dose-dependent TEAEs were observed. Flatulence occurred in 7.1% of participants in Part A and was the most frequently reported TEAE ( Table 2 ). All other TEAEs occurred in only one participant each (Tables 2 and 3) . Figure S1 ). The plasma concentration of enpatoran was found to increase rap- Nasopharyngitis - Table 4 ). The CL/F ranged from 120 to 162 L/h and was dose independent from 1 to 200 mg. Enpatoran PK parameters following the first dose in Part B (Day 1) were comparable with those found for single dosing (Tables 4 and 5 ). The geometric mean accumulation ratios for C max and AUC τ were Note: All values geometric mean (geometric coefficient of variation in percent) unless otherwise stated. Abbreviations: AUC 0-12 , area under the curve during 12 h; AUC 0-∞ , area under the curve from time of dosing extrapolated to infinity; AUC 0τ, area under the curve during 24 h for QD and 12 h for BID; BID, twice daily; C max , maximum plasma concentration; max, maximum; min, minimum; PK, pharmacokinetic; QD, once daily; R acc AUC τ , accumulation factor to assess the increase in exposure until steady state is reached; R acc C max , accumulation factor to assess the increase in maximum concentration until steady state is reached; t 1/2 , terminal half-life; t max , time to reach maximum plasma concentration. and C max decreased by 11% (fed versus fasting, 90% CI: 0.73, 1.09). In addition, CL/F decreased by approximately 25% and t max was delayed (3 h under fed compared with 1 h under fasting conditions). A similar trend was observed for enpatoran inhibition of IFNα ( Figure 5B ), although the inhibitory effect of enpatoran on IFNα was less potent than on IL-6. The TLR family of pattern recognition receptors are now recognized as having an important role in both innate and adaptive immunity and the body's normal defense against foreign molecules. However, evidence suggests that overactivation of TLR7 and TLR8 in response to endogenous RNA may drive the development and progression of certain autoimmune diseases, such as SLE, and therefore inhibition of such activation represents a possible therapeutic target. 6, 7 Also, inhibition of TLR7/8 at a critical point in the progression of COVID-19 may suppress the cytokine storm and improve survival outcomes. 18 Enpatoran is a small-molecule, dual TLR7 and TLR8 antagonist which has been shown in a range of in vitro assays and preclinical studies, including mouse models of SLE, to specifically inhibit TLR7/8 signaling. 21 In light of these positive preclinical findings, enpatoran warrants further investigation in human subjects to evaluate whether it similarly inhibits TLR7 and TLR8 activation, reduces cytokine secretion and modulates disease activity in patients with autoimmune diseases, such as SLE, and those with viral infections that stimulate this pathway. 2 As an initial step in clinical investigation, this FIH, phase 1, randomized, placebo-controlled study was undertaken to assess the safety, tolerability, PK, and PD of single and multiple daily doses of enpatoran up to 200 mg administered as a solution for 14 days and to explore the effect of food on the PK of enpatoran. F I G U R E 4 Mean (SD) enpatoran plasma concentration-time profiles following single administration in fasting (Study Part A) and fed (Study Part C) states (PK analysis set). PK, pharmacokinetic; SD, standard deviation The aim is to develop more effective treatments for notably difficult-to-manage autoimmune diseases, where there are often contraindications to currently available therapies. In the case of SLE, antimalarials have long been the cornerstone of treatment. Therapeutic options are sparse and off-label treatments are commonly used, including corticosteroids, mycophenolate mofetil, calcineurin inhibitors, and cyclophosphamide for extremely severe renal disease. 29 The monoclonal antibody belimumab is the only biologic agent approved for SLE to date. The selection of treatment depends on the patient's disease activity and comorbidities, and is most often limited by drug toxicities. 29 Through dual inhibition of TLR7 and TLR8, enpatoran has a broad inhibitory profile that differentiates it from existing SLE treatments, including belimumab which only targets B cells. There is also great interest in the use of TLR antagonists at a critical point in COVID-19 to reduce the hyper-inflammatory response and prevent progression to a cytokine storm. It is worth noting that, because the study population was limited to healthy volunteers, the results may not necessarily be generalizable to patients with SLE who have elevated cytokines correlating with active disease. In addition, the study was not designed to assess safety parameters over the long term and the preliminary assessment of dose proportionality is limited for the BID groups by the inclusion of only two dose levels. Evaluation of the safety and tolerability of enpatoran, which has dual TLR7/8 antagonist activity, and assessment of its PK and PD parameters in healthy individuals gives a clear indication that this molecule warrants further investigation as a potential treatment for diseases characterized by overactivation of TLR7 and TLR8. In light of these results, a phase 2 study of enpatoran in COVID-19 pneumonia (NCT04448756) and a phase 1b study of enpatoran in SLE (NCT04647708) are ongoing, both of which are exploring BID dosing regimens. The authors thank those who took part in the study. Germany, has a co-research, co-development, or co-marketing or co-promotion agreement, or when the product has been out licensed, the responsibility for disclosure might be dependent on the agreement between parties. Under these circumstances, the healthcare business of Merck KGaA, Darmstadt, Germany, will endeavor to gain agreement to share data in response to requests. Andreas Port https://orcid.org/0000-0002-5224-6593 Structural analyses of toll-like receptor 7 reveal detailed RNA sequence specificity and recognition mechanism of agonistic ligands TLR7 and TLR8 differentially activate the IRF and NF-kappaB pathways in specific cell types to promote inflammation Synthetic TLR agonists reveal functional differences between human TLR7 and TLR8 Kerdine-Römer S. TLR7 and TLR8 agonists trigger different signaling pathways for human dendritic cell maturation TLR7 and TLR8 activate distinct pathways in monocytes during RNA virus infection Toll-like receptors: potential targets for lupus treatment Toll-like receptors in systemic lupus erythematosus: potential for personalized treatment Nucleic acid sensors and type I interferon production in systemic lupus erythematosus Extracellular microRNAs induce potent innate immune responses via TLR7/MyD88-dependent mechanisms Immune stimulation mediated by autoantigen binding sites within small nuclear RNAs involves tolllike receptors 7 and 8 Association between toll-like receptor polymorphisms and systemic lupus erythematosus: a metaanalysis update TLR7-dependent and FcgammaRindependent production of type I interferon in experimental mouse lupus Toll-like receptor 7 and TLR9 dictate autoantibody specificity and have opposing inflammatory and regulatory roles in a murine model of lupus Yaa autoimmune phenotypes are conferred by overexpression of TLR7 Requirement of tolllike receptor 7 for pristane-induced production of autoantibodies and development of murine lupus nephritis Targeting human TLRs to combat COVID-19: a solution? In silico studies on the comparative characterization of the interactions of SARS-CoV-2 spike glycoprotein with ACE-2 receptor homologs and human TLRs Cytokine storm intervention in the early stages of COVID-19 pneumonia Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages Role of toll-like receptors in the pathogenesis of COVID-19 Discovery of M5049: a novel selective TLR7/8 inhibitor for treatment of autoimmunity Human TLR7 or TLR8 independently confer responsiveness to the antiviral compound R-848 P1-050 Model-informed dose selection of dual toll-like receptor 7/8 inhibitor M5049 for the treatment of COVID-19 pneumonia Inhibition of toll-like receptor-7 (TLR-7) or TLR-7 plus TLR-9 attenuates glomerulonephritis and lung injury in experimental lupus IMO-8400, a toll-like receptor 7, 8, and 9 antagonist, demonstrates clinical activity in a phase 2a, randomized, placebo-controlled trial in patients with moderate-to-severe plaque psoriasis Safety, pharmacokinetics, and pharmacodynamics in first-in-human study of a novel compound E6742, a toll-like receptor 7 and 8 antagonist Small-molecule inhibition of TLR8 through stabilization of its resting state Novel and selective TLR7 antagonists among the imidazo[1,2-a]pyrazines, imidazo[1,5-a]quinoxalines, and pyrazolo[1,5-a]quinoxalines series Systemic lupus erythematosus (SLE) therapy: the old and the new